[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Takeshita
Akihiro
A
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D000077237:Arsenic Trioxide; D001152:Arsenicals; D001565:Benzoates; D016572:Cyclosporine; D003561:Cytarabine; D003630:Daunorubicin; D015195:Drug Design; D051231:Farnesyltranstransferase; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009705:Nucleosides; D010087:Oxides; D011379:Prognosis; D011868:Radioisotopes; D012074:Remission Induction; D013764:Tetrahydronaphthalenes; D059003:Topoisomerase Inhibitors; D014212:Tretinoin; D014700:Verapamil
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D001565:Benzoates; D009705:Nucleosides; D010087:Oxides; D011868:Radioisotopes; D013764:Tetrahydronaphthalenes; D059003:Topoisomerase Inhibitors; D003561:Cytarabine; C061133:tamibarotene; D014212:Tretinoin; D016572:Cyclosporine; D000079982:Gemtuzumab; D014700:Verapamil; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D000077237:Arsenic Trioxide; D003630:Daunorubicin